MINERALYS THERAPEUTICS INC. - COMMON STOCK

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

25 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

13 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

05 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

14 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 06:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

02 May 2024 07:00:01 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

21 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

13 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces $120 Million Private Placement Financing

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

29 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

04 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

21 Dec 2023 15:05:03 By Nasdaq GlobeNewswire

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

11 Nov 2023 10:30:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in Three Upcoming Conferences

09 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 15:05:02 By Nasdaq GlobeNewswire

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023

31 Oct 2023 15:05:00 By Nasdaq GlobeNewswire